2023 Changping Forum on Financial Innovation in Medical and Health Industries: Empowering New Healthcare Tracks through Technology-Driven Finance

Whether in the primary market for equity investment or in healthcare industry financing and investment, fromPublic statistical data from the first half of 2023 indicate that the sector remained in a period of low activity. According to data from the VCBeat Orange Industry Database, total investment and financing in China’s healthcare industry exceeded USD 5.6 billion (approximately RMB 41.051 billion) in H1 2023, representing a year-on-year decline of over 43%. Investment sentiment cooled in both primary and secondary markets, with investors exercising greater caution; however, this environment accelerated the iteration and development of outstanding innovative enterprises in the pharmaceutical and healthcare sectors. Although the market is currently at an investment trough, substantial unmet clinical needs persist, underscoring the importance of maintaining confidence and patience in investing in the pharmaceutical and healthcare industries.

As IPO pathways narrow and the pace of listings slows, consolidation and M&A activity in the healthcare industry has accelerated significantly. Investment remains robust in niche sectors such as cell and gene therapy, interventional medical devices, synthetic biology, medical imaging, medical robotics, and AIGC. By deeply grasping the value of technology and innovation, balancing risk and return, and leveraging the synergy between domestic and international markets, investment institutions have iterated and upgraded their industrial investment logic.

In recent years, Beijing has attached great importance to the development of the biopharmaceutical industry. In accelerating the construction of an international science and technology innovation center, it has focused on deep cultivation in key areas such as scientific and technological innovation, biopharmaceuticals, and the digital economy, achieving fruitful results. As an important carrier area for Beijing’s International Science and Technology Innovation Center and a highland for innovation in Beijing’s pharmaceutical and health industry, Changping District is actively building multi-channel, multi-level enterprise service platforms, continuously promoting institutional innovation and supply chain openness in the biopharmaceutical industry.

November 17, 2023, Changping, Beijing,Hosted by the People's Government of Changping District, Beijing; co-organized by the Future Science City Management Committee (Life Science Park Management Committee), the Management Committee of Zhongguancun Science Park Changping Park, the Financial Services Office of Changping District, Beijing, Beijing Changping Science Park Development Co., Ltd., Beijing Zhongguancun Life Science Park Development Co., Ltd., and VCBeat VB100The 2023 Changping Pharmaceutical and Health Investment Innovation Forum will leverage Changping District’s unique industrial and financial resource advantages, inviting a host of prominent guests and high-level industry figures from the medical and health ecosystem—including government officials, academicians and scientists, clinical experts, top-tier investors, and corporate leaders—to explore value investment and value creation in the future pharmaceutical and health industries.

Leading Experts Convene to Discuss Basic Research, Original Innovation, and the Future of Industry

This forum has invited government leaders, academicians of learned societies, key executives from stock exchanges, clinical scholars in the domestic pharmaceutical and healthcare sectors, managers of medical and health institutions, representatives of listed companies, representatives of innovative enterprises, and representatives of renowned financial investment institutions to participate. The event aims to gather cutting-edge research insights, explore trends in industrial investment, and jointly discuss the new future of the pharmaceutical and healthcare industry.

Precise Data: Insights into the 2023 Global Healthcare Industry Trends

The “2023 Global Healthcare Industry Capital Report” will be prominently released at the forum and interpreted on-site by experts from VCBeat. Based on global healthcare information archived in VBInsight (VCBeat’s Orange Industry Think Tank), the report cleanses over 42,000 financing data entries to substantiate the changing trends of the global healthcare industry in 2023 with authentic investment and financing data, thereby helping industry practitioners gain insights into capital dynamics. Against the backdrop of emerging technologies entering the market, shifts in global demographic structures, ongoing regional international conflicts, upstream supply chain shortages, and medical institutions’ efforts to reduce costs and improve efficiency, the report focuses on analyzing data across dimensions such as high-potential healthcare sectors, financing stages, popular cities/industrial clusters for investment and financing, and active healthcare investment institutions. It also provides an outlook on investment and financing trends in pharmaceuticals and healthcare, aiming to offer investment references for the industry.

Major Signing: Uniting Forces to Leverage the Key Role of Investment

As one of Changping District’s three innovation industry clusters each valued at over RMB 100 billion, the pharmaceutical and healthcare sector has gathered more than 900 innovative enterprises and over 300 top-tier global innovators, making it one of the fastest-growing industries. After more than a decade of development and maturation, high-quality investment opportunities have continued to emerge in recent years. As of the end of October 2023, the fund-of-funds system under Changping Development had partnered with 44 market-oriented investment funds, directly or indirectly invested in over 1,100 projects, seen 38 portfolio companies list on secondary markets, and was actively facilitating the IPO processes of more than 30 additional companies. Changping Development provides in-depth support for the district’s three leading advantageous industries—pharmaceuticals and healthcare, advanced energy, and advanced manufacturing—while placing particular emphasis on enabling and nurturing sectors such as the digital economy. It is committed to strengthening a full-lifecycle, sustainable, and positively reinforcing fund investment ecosystem to serve and support the long-term, healthy development of regional industries and the economy.It is understood that Changfa Development is further deepening its cooperation models with various partner funds and exploring new opportunities for collaboration.This forum features a special signing ceremony, during which Chang Development will sign agreements on-site with its partner funds to further leverage its investment capabilities while expanding its footprint.'s pivotal role, empowering the innovation ecosystem and accelerating industrial upgrading.We cordially invite colleagues from the pharmaceutical and health industries to witness this signing ceremony.

Focusing on Hot Sectors, Envisioning the New Future of the Industry

This forum will feature four roundtable discussions with 28 guest speakers, who will delve into development trends and investment hotspots in niche sectors across four thematic sessions: “Innovative Pharmaceuticals,” “Innovative Medical Devices,” “Industrial Ecosystem,” and “Capital Perspectives.” Below are the selected topics for these four roundtables.

●What is the significance of source innovation and achievement transformation for the innovative drug industry? How should pharmaceutical companies formulate their development strategies based on patients' clinical needs?

● What new changes are occurring in China’s medical device industry? Regarding the challenging topic of Chinese medical device companies breaking into overseas markets, what are the converging and diverging views held by enterprises and investment institutions?

● Against the backdrop of the imperative for high-quality corporate development, how can industrial parks and accelerators coordinate the needs of diverse stakeholders? How can they cultivate more attractive and competitive service models?

● In a volatile and complex macroeconomic environment, how can investors distinguish between what is changing and what remains constant? How can they seize investment opportunities in niche sectors and identify long-term value that transcends industry cycles?

09:30-09:35

▸ Host's Opening Remarks

09:35-09:50

▸ Forum Address

09:50-10:20

▸ Synthetic Biology and Biomanufacturing

Zhang Xian’en | Vice President of the Chinese Society for Biotechnology, Director of the Synthetic Biology Branch

10:20-10:40

▸ High-Quality Development of the Beijing Stock Exchange to Support Corporate Innovation

Leader in Charge of the Beijing Stock Exchange

10:40-11:00

▸ Leveraging the Advantages of Insurance Capital to Support Innovative Development in the Medical, Elderly Care, and Health Industries

Chen Youtang | Deputy Secretary-General of the Insurance Asset Management Association of China

11:00-11:40

▸ The Role of Basic Research and Original Innovation in Driving Industrial Development

Liu Guoen | Dean of the Institute for Global Health Development at Peking University, Member of the Faculty of the Chinese Academy of Medical Sciences

Xiao Zhi | Co-Head of SDIC Investment Promotion’s Life Sciences Team, Managing Director

Xie Xin | Executive Director and Senior Vice President, China Biopharmaceutical

11:40-11:50

▸ Signing Ceremony for the Cooperative Fund

11:50-12:00

▸ 2023 Global Healthcare Industry Capital Report

Bi Yuanfeng | Co-founder and COO of VCBeat

12:00-14:00

▸ Lunch Break

14:00-15:00

▸ Strategies for Chinese Innovative Pharmaceutical Companies to Balance Breakthroughs and Stability for Long-Term Development Amidst the Emphasis on Source Innovation and Commercialization of Achievements

Roundtable Moderator:Gao Jieliang | CDH Innovation & Growth FundPartner

Roundtable Guests:

Li Qichen | Co-founder and General Manager of Yiming Cell

Shang Yuanfang | Founder and CEO of CytoNest

Tian Wenzhi | Chairman, CEO, and CSO of ImmuneOnco

Xu Qian | General Manager and Managing Partner, Danlu Capital Beijing

Yang Bin | Director, Center for Smart Health, Institute for Precision Medicine, Tsinghua University

Zhang Yi | Managing Partner, Huagai Medical Early-Stage Fund

15:00-16:00

▸ Strategies for Chinese Medical Device Companies to Break the Ice Amidst Great Power Competition

Roundtable Moderator: Tang Haofu | Partner, Chongqing Dianshi Chuangjian Fund / Shanghai Chuangrui Fund

Roundtable Guests:

Bai Yuan | Co-founder and Deputy General Manager of Huapu Instruments

Jie Jing | CTO of Weimai Medical

Zhang Jiang | Founder and CEO, LRI Jiangyuan Investment

Zhang Yiling | Chairman of Changmugu

Zhu Zhicheng | Deputy General Manager of Jiuyiyuan

Zhou Yixin | Director of the Department of Orthopedic Surgery, Beijing Jishuitan Hospital; Professor, Peking University Health Science Center

16:00-17:00

▸ Pathways for Service and Operation Agencies to Enhance Performance under the Requirements of High-Quality Development in Industrial Parks

Roundtable Moderator: Li Yang | Head of Yuanyi Digital Health Accelerator

Roundtable Panelists:

Kang Haihua | Senior Managing Director at Qiao Capital and CEO of the Qiao Healthcare Industry Facilities Platform

Wang Hui | Founder of Hongrun Health Group

Zang Dongning | Vice President of Clinical Development, Thermo Fisher Scientific China

Zhao Weiwen | General Manager, BGI Blue Rainbow Life Science Accelerator

Zheng Xiaoyu | Executive Dean of Beijing Gaobo Hospital and Beijing Gaobo Boren Hospital

Zhuang Jia | Head of Innovation Department, ATLATL; Executive Director, ATLATL Venture Capital

17:00-18:00

▸ The Path to Survival for Capital and the Pharmaceutical Industry Amid a Complex Macroeconomic Environment

Roundtable Moderator: Tao Yu | Executive General Manager, Changkejin Company

Roundtable Guests:

Li Fan | Fosun Global Partner, CEO of Fosun Rehab Capital

Li Jiangfeng | Partner, Fortune Capital

Liu Yu | General Manager and Managing Partner, BGI Win-Win

Shi Huijing | Founding Partner, Yahui Investment

Zhao Gang | Partner, SoftBank China Capital

Forum Name:2023 Changping Medical and Health Finance Investment Innovation Forum

Forum Schedule:November 17, 2023

Forum Venue:Lecture Hall, 1st Floor, Taikang Institute of Learning, Changping, Beijing

Forum Scale:300-400 people

Forum Organizing Committee:

· Organizer:

People's Government of Changping District, Beijing Municipality

·Organizer:

Future Science City Management Committee (Life Science Park Management Committee)

Management Committee of Changping Park, Zhongguancun Science Park

Financial Services Office of Changping District, Beijing Municipality

Beijing Changping Science Park Development Co., Ltd.

Beijing Zhongguancun Life Science Park Development Co., Ltd.

Beijing Danhuang Technology Co., Ltd. (VCBeat VB100)

· Forum Registration ·

Scan the QR code to register for free and join the forum discussion group.

Ticket Benefits:

1. Includes the report released at this forum (electronic version)

2. On-site Resource Coordination Group

3. Transcripts of Selected Guest Speeches and Roundtable Discussions at This Forum

4. Forum Lunch Voucher

As the forum approaches, the Organizing Committee cordially invites enterprises and institutions within the Changfa Zhan ecosystem, as well as pharmaceutical and healthcare companies and investment firms, to submit congratulatory video messages. The compiled highlights of these videos will be featured as a looping pre-event presentation during the forum. We look forward to your participation.

Call for Video Submissions

1. Brief introduction of the recorder and their affiliated enterprise/institution;

2. Wishes for the Forum: We wish the 2023 Changping Pharmaceutical Health Financial Investment and Innovation Forum a complete success!

Primary Video Promotion Channels

1. Forum Warm-up Video

2. VB100 Video Channel, Chang Development Video Channel, and conduct community promotion

Recording Precautions

1. On-camera talent: It is recommended that the company’s founder/CEO appear on camera for the recording;

2. Recording equipment: mobile phones, camcorders, or DSLR cameras;

3. Aspect ratio: 16:9 landscape; keep the shot level and stable, preferably using a tripod;

4. Recording duration: less than 1 minute;

5. Resolution: 1080P and above;

6. Recording Environment: Record in a quiet and well-lit environment;

7. Recording Background: The background should be simple and clean;

8. Subject Positioning: The subject should stand or sit upright, with the upper body captured on camera;

9. Audio Recording: Recordings must be in Mandarin, with a loud and clear voice;

10. Recording Atmosphere: The overall atmosphere should be bright and generous, relaxed and comfortable;

11. Video Submission Deadline: November 10. Please send recorded videos to peng.x@vcbeat.net.

Scan the QR code below to add our staff on WeChat for more details on blessing videos and to submit your video.

(Please be sure to state your purpose when adding: Name + Position + Changping Forum Greeting Video)

·Media Partners·

·Contact Us·

Conference Inquiry: [VB100] Ms. Peng - 13364027163 (WeChat ID same)

Media Cooperation: [VB100] Ms. Zou - 15213067481 (WeChat ID same as phone number)